Please login to the form below

payors

This page shows the latest payors news and features for those working in and with pharma, biotech and healthcare.

prevents “rival drugs from obtaining access to payors’ formularies, resulting in reduced consumer choice”.

FDA’s Gottlieb lambasts industry’s biosimilar-blocking tactics

He said in a speech to the Brookings Institute this week that branded drugmakers “thwart competition by dangling big rebates to lock up payors in multi-year contracts right on the
Merck & Co gets EU green light for hep C drug Zepatier

Part D and other payor formularies.
Novel drugs and rare diseases drive US prescription drug spend

The data indicates that increased competition between manufacturers as well as more aggressive efforts by payors to limit prescription drug spending is resulting in price concessions.
Valeant shares slide on fears of filing default

of our constituencies - physicians, patients, employees, payors, debt holders and shareholders".
US ruling clears Novartis' Zarxio but could delay other biosimilars

The high revenues achieved by many biologic drugs means that any delay to the onset of biosimilar competition can have a massive impact on both brand-name companies and healthcare payors.

More from news
Approximately 0 fully matching, plus 20 partially matching documents found.

Patient centricity in pharma: musings of a doctor turned medical writer

In med comms, we develop a huge range of activities and materials that will affect healthcare professionals, payors and the patient. ... Naturally, it would be important to tailor the illustration of the sustainability and value of these outcomes to the
Dice Medical Communications

Brands nurtured with Pharmacohesion thrive because:. Customers – whether they are prescribers, payors, carers or patients – know exactly what to expect from your brand in terms of how it impacts their lives.
Tapping the potential of rare diseases: A journey into uncharted territory

Costs per treatment can often be high, and this must be effectively justified to payors through the appropriate HTA or equivalent route.
Porterhouse celebrates 12 months of smarter insight-driven medical communications

Areas of expertise include:. Identifying unmet needs Market understanding Opportunity assessments Attribute prioritisation Scenario planning Demand estimation Patient journey mapping Positioning and communications Payor insights Behavioural change.
Practical Patient Centricity

Though the pharmaceutical industry has multiple customers, including healthcare professionals and payors, the ultimate customers are always patients.

More from PMHub
Approximately 0 fully matching, plus 10 partially matching documents found.

Country Manager, Healthcare Communications Agency, Germany: Highly competitive salary

Add my company

We’re a specialist health consultancy that supports companies, healthcare professionals and patients to work hand in hand with a common...

Environment: where does the pharmaceutical industry stand?: ...
The communication challenge of helping he next generation to be healthier: As the pressure on the health service increases the health of the next generation is vital for everyone. How do we show positive attitudes and change behaviour while future proofing...
Are we losing sight of what the democratisation of healthcare really looks like?: We have a core responsibility as healthcare communicators to consistently drive for better inclusion, engagement and compliance. What does the ‘democratisation of healthcare’ really look like?...

Email:
Password: